• The Centers for Medicare & Medicaid Services previously issued an updated National Coverage Determination that broadened access to transcatheter aortic valve replacement (TAVR), aligning with Edwards Lifesciences’ Sapien 3 devices that already carry expanded FDA labels for asymptomatic patients.
• This clearer and more inclusive reimbursement framework could be pivotal for Edwards Lifesciences’ transcatheter heart valve portfolio by supporting wider real-world adoption and potentially shifting share within the TAVR market.
• Next, we’ll examine how this expanded CMS coverage for TAVR shapes Edwards Lifesciences’ investment narrative and future growth opportunities.

The future of work is here. Discover the 32 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

What Is Edwards Lifesciences' Investment Narrative?

For Edwards Lifesciences, the big-picture belief is that structural heart therapies like TAVR, mitral and tricuspid repair and replacement, and RESILIA-based valves can keep gaining clinical traction and support steady, if not spectacular, financial progress. The new CMS National Coverage Determination for TAVR fits squarely into that thesis, because broader and clearer reimbursement can reinforce Edwards’ existing FDA label position in asymptomatic patients and support near-term procedure volumes, a key catalyst given current sales guidance of US$6.5 billion to US$6.9 billion for 2026. At the same time, the stock still carries a rich earnings multiple, recent profit margins have been pressured by one-off items, and the company faces ongoing competitive risks from other valve makers even if CMS coverage modestly shifts share in its favor. Investors now need to weigh a potentially stronger TAVR backdrop against valuation and execution risks.

However, investors should also consider how rich expectations and competition could limit the upside. Edwards Lifesciences' shares have been on the rise but are still potentially undervalued by 5%. Find out what it's worth.

Exploring Other Perspectives

Three Simply Wall St Community members currently see Edwards Lifesciences’ fair value clustered between about US$91.50 and US$96.92, underscoring how tightly some private investors group their expectations. Set that against the evolving CMS coverage for TAVR and the company’s premium earnings multiple, and it is clear you are weighing both improved access to key therapies and the risk that execution or competition could challenge those optimistic views.

Explore 3 other fair value estimates on Edwards Lifesciences - why the stock might be worth as much as 12% more than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Edwards Lifesciences research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Edwards Lifesciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Edwards Lifesciences' overall financial health at a glance.

Curious About Other Options?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• Outshine the giants: these 14 early-stage AI stocks could fund your retirement.
• This technology could replace computers: discover 29 stocks that are working to make quantum computing a reality.
• Uncover the next big thing with 24 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.